At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...

Sonrotoclax demonstrated a total overall response rate of 52%, including a complete response rate of 16%. However, Wang ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

Treatment with a CAR-T cell therapy showed promise in patients with mantle cell lymphoma, potentially leading to a new option for a group of individuals who have exhausted other options. Treatment ...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

ATLANTA--(BUSINESS WIRE)--Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced clinical study results using the ...

HIV virus Recommendations for initiation of antiretroviral therapy (ART) in asymptomatic adults with HIV are generally based on CD4 T-cell counts. The START trial included 4,685 adults (mean age, 36 ...